1. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data
- Author
-
Nina Isoherranen, Chi Chi Peng, Connie L. Davis, Ian Templeton, Kenneth E. Thummel, and Kent L. Kunze
- Subjects
Adult ,Male ,Itraconazole ,Metabolic Clearance Rate ,Metabolite ,Midazolam ,Pharmacology ,In Vitro Techniques ,Article ,chemistry.chemical_compound ,Inhibitory Concentration 50 ,Young Adult ,Pharmacokinetics ,In vivo ,medicine ,Cytochrome P-450 CYP3A ,Humans ,Pharmacology (medical) ,Drug Interactions ,Enzyme Inhibitors ,CYP3A4 ,Dose-Response Relationship, Drug ,Dose–response relationship ,chemistry ,Pharmacodynamics ,Area Under Curve ,Cytochrome P-450 CYP3A Inhibitors ,Female ,Drug metabolism ,medicine.drug - Abstract
Inhibitory drug metabolites may contribute to drug-drug interactions (DDIs). The aim of this study was to determine the importance of inhibitory metabolites of itraconazole (ITZ) in in vivo cytochrome P450 (CYP) 3A4 inhibition. The pharmacokinetics of ITZ and midazolam (MDZ) were determined in six healthy volunteers in four sessions after administration of MDZ with and without oral ITZ. After doses of 50, 200, and 400 mg of ITZ, the clearance of orally administered MDZ decreased by 27, 74, and 83%, respectively. The in vivo half maximal inhibitory concentration (IC(50)) for ITZ ranged from 5 to 132 nmol/l in the six subjects. The metabolites of ITZ were estimated to account for ~50% of the total CYP3A4 inhibition, with the relative contribution increasing with time after ITZ dosing. Of the total of 18 interactions observed, 15 (84%) could be predicted within a twofold error margin, with improved accuracy observed when ITZ metabolites were included in the predictions. This study shows that the metabolites of ITZ contribute to CYP3A4 inhibition and need to be accounted for in quantitative rationalization of ITZ-mediated DDIs.
- Published
- 2010